PiperJaffray: Can UK Biotech Survive the Current Financial Climate?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: PiperJaffray: Can UK Biotech Survive the Current Financial Climate?
Released on: September 16, 2008. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this edition of ‘The Financial Report’ brought to you by PharmaVentures Business Review, Fintan Walton talks to Sam Fazeli, Managing Director of European Equity Research at PiperJaffray.

They discuss issues in the biotech industry with reference to the current financial climate and the need for governments to nurture the scientific and technology industry sectors. Sam Fazeli gives us an insight into the cyclic nature of the biotech industry and its relation to product success, share prices and investor risk appetites. Although voicing some concern about the number of biotech companies lower down the pipeline in the UK he finishes with a look at all the positive aspects of the industry.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Position of the UK biotech industry in the current financial climate
Fintan Walton:
Hello and welcome to PharmaVentures business review here in London. On this show I have Sam Fazeli, who is Managing Director of European Equity Research at Piper Jaffray. Welcome to the show.
Sam Fazeli :
Thank you very much. Good morning.
Fintan Walton:
Sam Fazeli, you have a significant amount of experience from a investment banking perspective of what's going on in the biopharmaceutical industry particularly here in the UK, but also you have obviously a good eye and experience with the European markets as well. And how would you describe Sam Fazeli, the – from your perspective the state of biotech here in the UK, okay?
Sam Fazeli :
Sure. We've had – we are obviously the markets in general, equity markets in general, capital markets, or financial markets are in turmoil at the moment. So it's difficult to make conclusions about the state of the industry from just looking at it today.
Fintan Walton:
Right.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Sam Fazeli
Managing Director of European Equity Research
Sam Fazeli , Ph.D., is a managing director and senior research analyst focused on U.K. biopharmaceutical stocks. Sam Fazeli joined Piper Jaffray in 2005. His initial coverage focus is on U.K. biopharmaceutical companies, but will expand to cover continental European biopharmaceutical companies. Sam Fazeli has 10 years' experience in the biopharmaceutical sector. Previously, he was at Nomura where he was part of a team that was ranked No. 1 in the U.K. in the September 2004 Institutional Investor Survey of U.K. Small Cap Fund Managers. In 2005, Sam Fazeli was ranked eighth in the Extel Pan-European Biotech Survey. Sam Fazeli has a Ph.D. in Pharmacology and seven years' post-doctoral experience.
Piper Jaffray
Piper Jaffray Companies is a middle-market investment bank and institutional securities firm, serving the needs of middle-market corporations, private equity groups, public entities, nonprofit clients and institutional investors. The Company provides a set of products and services, including equity and debt capital markets products; public finance services; mergers and acquisitions advisory services; high-yield and structured products; institutional equity and fixed income sales and trading; equity research, and asset management services. The Company's operations consist principally of four components: Investment Banking, Equity and Fixed Income Institutional Sales and Trading, Asset Management and Other Income. Piper Jaffray operates predominantly in the United States. It also provides investment banking, research, and sales and trading services to selected companies in international jurisdictions in Europe and Asia. It markets its investment banking and institutional securities business under a single name, Piper Jaffray. Its asset management business is marketed under the name of FAMCO, which is derived from its subsidiary, Fiduciary Asset Management.